Cargando…

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension

Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raina, Amresh, Coons, James C., Kanwar, Manreet, Murali, Srinivas, Sokos, George, Benza, Raymond L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ https://www.ncbi.nlm.nih.gov/pubmed/23662183 http://dx.doi.org/10.4103/2045-8932.109926

Ejemplares similares

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
por: Coons, James C., et al.
Publicado: (2018)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
por: Maestas, Travis, et al.
Publicado: (2018)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
por: Mirza, Shireen, et al.
Publicado: (2012)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
por: Coons, James C., et al.
Publicado: (2021)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
por: Balasubramanian, Vijay P., et al.
Publicado: (2022)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension
por: Gleason, James Benjamin, et al.
Publicado: (2015)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
por: Coons, James C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cdogaqq3o4j05lg09e819aps3e